Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$32.76 - $39.56 $2.33 Million - $2.82 Million
71,200 Added 33.78%
282,000 $9.86 Million
Q4 2023

Feb 14, 2024

SELL
$14.5 - $38.0 $1.44 Million - $3.78 Million
-99,400 Reduced 32.04%
210,800 $8.01 Million
Q3 2023

Nov 14, 2023

BUY
$15.75 - $26.31 $270,900 - $452,532
17,200 Added 5.87%
310,200 $5.69 Million
Q2 2023

Aug 14, 2023

BUY
$16.96 - $27.82 $323,936 - $531,362
19,100 Added 6.97%
293,000 $7.61 Million
Q1 2023

May 15, 2023

BUY
$18.45 - $27.14 $1.24 Million - $1.82 Million
67,100 Added 32.45%
273,900 $5.17 Million
Q4 2022

Feb 14, 2023

BUY
$20.18 - $33.33 $1.15 Million - $1.9 Million
57,000 Added 38.05%
206,800 $5.1 Million
Q3 2022

Nov 14, 2022

BUY
$11.58 - $24.73 $1.22 Million - $2.61 Million
105,600 Added 238.91%
149,800 $2.69 Million
Q2 2022

Aug 15, 2022

BUY
$8.52 - $25.26 $235,152 - $697,176
27,600 Added 166.27%
44,200 $502,000
Q1 2022

May 16, 2022

BUY
$19.89 - $43.18 $330,174 - $716,788
16,600 New
16,600 $370,000
Q2 2021

Aug 16, 2021

SELL
$14.69 - $27.52 $154,245 - $288,960
-10,500 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$16.27 - $41.26 $170,835 - $433,230
10,500 New
10,500 $211,000

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.